AXA Framlington Biotech GBP Z Acc (FUND:B784NS1) - Fund price


Fund Report

AXA Framlington Biotech Fund GBP Z Acc

  • Fund: AXA Framlington Biotech Fund GBP Z Acc
  • Category: Sector Equity Biotechnology
  • Benchmark: NASDAQ Biotechnology TR USD

Growth Of 100 (GBP) 31/05/2021

How has this security performed
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
  • 2019
  • 2020
  • 2021
Annual Returns % (GBP) 31/05/2021
20142015201620172018201920202021
Fund46.6812.29-4.959.66-6.4219.3532.74-7.59
Category38.5413.41-3.9610.29-7.9620.2025.97-6.99
Benchmark42.7618.24-6.1811.10-3.2020.2822.52-3.42
% Rank (Rel to Cat)2066516250581863
Quartile RankQuartile1Quartile3Quartile3Quartile3Quartile2Quartile3Quartile1Quartile3
Trailing Returns % (GBP) 21/06/2021
FundCategoryBenchmark
1 Day-0.15-0.370.11
1 Week-0.53-0.560.34
1 Month7.075.987.74
3 Months4.441.662.64
6 Months-2.74-6.87-1.66
YTD0.25-3.144.16
1 Year4.160.933.74
3 Years Annualised9.186.8111.31
5 Years Annualised15.1013.9215.38
10 Years Annualised18.7416.3018.92
Quarterly Returns % (GBP) 31/03/2021
Quarter 1Quarter 2Quarter 3Quarter 4
2021-6.26---
20200.3429.26-2.284.73
201916.130.06-9.0512.94
2018-1.609.3610.78-21.50
20177.481.804.29-3.90
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.